Abstract Library

#4151 Identifying potential tumor drivers through integration of gene expression and DNA copy number in SI-NET

Introduction: The genetics of small intestine neuroendocrine tumors (SI-NETs) remains poorly understood. To date, only CDKN1B has been found recurrently mutated, in approximately 9% of cases. On the contrary, DNA copy number alterations are found in a majority of cases. The most frequent aberration is heterozygous loss of chromosome 18. In addition, loss of chromosome 11, and gains on chromosomes 4, 5 and 14 are common. The cellular mechanisms through which these alterations drive tumor development are unknown.

Conference:

Presenting Author: Backman S

Authors: Backman S, Barazeghi E, Norlén O, Hellman P, Stålberg P,

Keywords: SI-NET, RNA-Seq, Gene dosage, Haplo-insufficiency, Copy number,

#4036 Metformin inhibits small intestinal neuroendocrine tumor proliferation in vivo

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow-growing, with most patients being diagnosed at a late stage with distant metastases. Metformin has been hypothesized as a potential anti-tumor agent by several studies in the past few years. This has been further confirmed by experimental studies in which metformin has inhibited cancer cell growth in different cancers, and we recently demonstrated that metformin treatment repressed the cell viability of SI-NET cells and inhibited the proliferation of cell spheroids.

Conference:

Presenting Author:

Authors: Axling F, Hellman P, Norlén O, Stålberg P, Barazeghi E,

Keywords: neuroendocrine neoplasm, SI-NET, in vivo model, metformin, RNA-seq, miRNA-seq, xenograft,

#3721 No multiple endocrine neoplasia type 1 (MEN1) Patient died from pancreaticoduodenal neuroendocrine tumor – Results from long-term follow-up of the Uppsala model of early diagnosis and treatment

Introduction: Progression of pancreaticoduodenal neuroendocrine tumor (P-NET) disease is the main death cause among MEN1 carriers. Although surgery is the only cure, indications vary substantially between centers. The Uppsala model of MEN1 management encompasses early diagnosis and treatment, aiming at lifelong malignancy prevention with preserved endocrine function. During three decades, all MEN1 patients harbouring P-NETs of at least 1 cm have been considered for surgery.

Conference:

Presenting Author:

Authors: Bajic D, Kjaer J, Welin S, Norlén O, Öberg K,

Keywords: multiple endocrine neoplasia type 1, pancreatic neuroendocrine tumor, indication for surgery, malignancy prevention,

#3630 Metformin suppresses small intestinal neuroendocrine tumor growth in vivo

Introduction: Small intestinal neuroendocrine tumors (SI-NETs) are rare and slow growing, but most patients are diagnosed at a late stage with distance metastases. In the past few years, several studies have reported the anti-tumor activity of metformin in different cancers, and recently we showed that metformin treatment repressed cell viability of SI-NET cells and inhibited the growth of GOT1 spheroids.

Conference:

Presenting Author:

Authors: Barazeghi E, Axling F, Hellman P, Norlén O, Stålberg P,

Keywords: neuroendocrine tumor, metformin, SI-NET xenograft,

#3310 Ectopic Cushing’s syndrome: Experience from a tertiary care center

Introduction: Neuroendocrine neoplasms (NENs) causing ectopic Cushing’s syndrome (ECS) are relatively rare and very challenging to treat.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lase I

Authors: Lase I, Grönberg M, Strele I, Kozlovacki G, Norlën O,

Keywords: Ectopic Cushing’s syndrome, ACTH, neuroendocrine, hypercortisolism, multiple hormone secretion, bilateral adrenalectomy,